We are live on
!
Find out more
ACA
Avoro Capital Advisors Portfolio holdings
AUM
$11.1B
1-Year Est. Return
207.82%
This Fund
S&P 500
This Quarter
Est. Return
+29.18%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$11.1B
AUM Growth
+$971M
(+9.6%)
Cap. Flow
-$906M
Cap. Flow
% of AUM
-8.14%
Top 10 Holdings %
Top 10 Hldgs %
79.46%
Holding
34
New
2
Increased
12
Reduced
3
Closed
8
Avg Time Held Equity + Options
10.4
quarters
Top 10 Avg Time Held Equity + Options
9.9
quarters
Top 20 Avg Time Held Equity + Options
9.2
quarters
Avg Time Held Equity only
10.4
quarters
Top 10 Avg Time Held Equity only
9.9
quarters
Top 20 Avg Time Held Equity only
9.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cytokinetics
CYTK
|
+$120M |
| 2 |
United Therapeutics
UTHR
|
+$83.2M |
| 3 |
Definium Therapeutics
DFTX
|
+$54.1M |
| 4 |
Hemab Therapeutics
COAG
|
+$53.1M |
| 5 |
Arrowhead Research
ARWR
|
+$48.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apellis Pharmaceuticals
APLS
|
+$492M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$454M |
| 3 |
Terns Pharmaceuticals
TERN
|
+$300M |
| 4 |
Soleno Therapeutics
SLNO
|
+$77M |
| 5 |
Alkermes
ALKS
|
+$42.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Lexeo Therapeutics
LXEO
$250M
| $6.93M | 0.06% |
1,489,189
-385,811
| -21% | -$2.09M |
2025 Q4
2 quarters
|
|
|
27
Alkermes
ALKS
$6.75B
| – | – |
-1,200,000
| Closed | -$42.4M | – |
|
|
28
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-12,222,222
| Closed | -$492M | – |
|
29
CALL
Celcuity
CELC
$3.22B
| – | – |
-200,000
| Closed | -$3.05M | – |
|
|
CNTA
30
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-11,430,455
| Closed | -$454M | – |
|
31
MannKind Corp
MNKD
$1.01B
| – | – |
-2,200,000
| Closed | -$5.39M | – |
|
|
32
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-2,300,000
| Closed | -$77M | – |
|
|
33
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-5,695,000
| Closed | -$300M | – |
|
|
34
CALL
United Therapeutics
UTHR
$23.6B
| – | – |
-380,000
| Closed | -$10.3M | – |
|
Similar funds
GI
BEI
VNIM
MF
MC
GJL
LCAM
IIM
Avoro Capital Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Avoro Capital Advisors held 34 positions worth $11.1B, up 9.6% from $10.2B the previous quarter. Its ten largest holdings account for 79% of the portfolio.
Avoro Capital Advisors withdrew a net $906M in Q2 2026, closing 8 positions and reducing 3 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $492M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.
Against the trend, Avoro Capital Advisors opened a new position in Hemab Therapeutics worth $70.7M.
- Avoro Capital Advisors's largest Q2 2026 buy was Hemab Therapeutics: 1,925,150 shares worth $70.7M.
- Avoro Capital Advisors added most to Cytokinetics in Q2 2026, an estimated $120M increase.
- Avoro Capital Advisors's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $6.93M.
- Avoro Capital Advisors fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $492M.
- Avoro Capital Advisors's ten largest holdings make up 79% of its $11.1B portfolio in Q2 2026.
- Avoro Capital Advisors opened 2 new positions and closed 8 in Q2 2026.
- Avoro Capital Advisors's portfolio value rose 9.6% quarter-over-quarter to $11.1B.
Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.